Reuters (11/25/15) Berkrot, Bill

Amgen has filed for approval from U.S. health regulators to sell its biosimilar of AbbVie's Humira (adalimumab). Amgen reports that its biosimilar, called ABP 501, has shown clinical equivalence and comparable safety to Humira in late-stage clinical trials for rheumatoid arthritis and plaque psoriasis. The regulatory submission to regulators included data that supports switching patients from Humira to ABP 501.

Web Link 

Abstract News © 2016 INFORMATION, INC.

Access other Therapeutic Areas:


 

New & Noteworthy